IceCure Medical

IceCure Medical develops and markets minimally invasive cryoablation therapies for women's health and the general oncology market. The company's proprietary IceSense3 and ProSense systems provide minimally invasive, in-office definitive treatment for symptomatic tumors in various organs.

The procedure is done under ultrasound or CT imaging to guide a small probe (thin hollow needle) into the tumor. The system then uses extremely cold temperatures to ablate the targeted tumor in situ. The cryoablation procedure is a safe and effective treatment option that can be performed quickly in a doctor's office.

IceCure has FDA and CE approval for broad benign and malignant indications. The company's ProSense is available in the United States, Europe, Hong Kong, Thailand, Singapore, Central America, and South America. The company is also undergoing the regulatory process in China with the CFDA as well as other Asian and South American countries. It is currently participating in several clinical studies for the treatment of lung, kidney, and breast cancer (under clinical studies in the United States and Japan).

In January 2020, it was cleared by the FDA to use its tumor-freezing technology on additional types of cancers (it was already cleared for use on breast cancer patients).

Primary Sector

Products

Geographic markets

Champions Oncology

Personalized Cancer Treatment

BiomX

Microbiome Therapies for Chronic Diseases

Exalenz Bioscience

One-step Urea Breath Test

Alpha Tau Medical

Cancer Radiotherapy

UroGen Pharma

Urologic Oncology Therapies

And much more...